{"contentid": 488400, "importid": NaN, "name": "Encouraging Phase II data for Alzheimer's candidate BAN2401", "introduction": "Japanese drugmaker Eisai, one of an increasingly small number of major players still working in the Alzheimer\u00e2\u0080\u0099s space, has published results from a Phase IIb trial of lecanemab.", "content": "<p><span style=\"font-weight: 400;\">Japanese drugmaker Eisai (TYO: 4523), one of an </span><a href=\"https://www.thepharmaletter.com/article/another-phase-iii-failure-shakes-amyloid-beta-model-of-alzheimer-s\"><span style=\"font-weight: 400;\">increasingly small</span></a><span style=\"font-weight: 400;\"> number of major players still working in the Alzheimer&rsquo;s space, has published results from a Phase IIb trial of lecanemab.</span></p>\n<p><span style=\"font-weight: 400;\">Lecanemab, also known as BAN2401, is a monoclonal antibody subject to a strategic research alliance between Eisai and Sweden&rsquo;s BioArctic (Nasdaq Stockholm: BIO B).</span></p>\n<p><span style=\"font-weight: 400;\">Since 2019, the firms have been </span><a href=\"https://www.thepharmaletter.com/article/eisai-makes-milestone-payment-in-alzheimer-s-collaboration-with-bioarctic\"><span style=\"font-weight: 400;\">working together</span></a><span style=\"font-weight: 400;\"> to characterize and test the investigational biologic in this therapy area.</span></p>\n<p><span style=\"font-weight: 400;\">The latest results, from Study 201, show the impact of treatment with lecanemab on reducing brain amyloid beta (A&beta;) and clinical decline.&nbsp;</span></p>\n<p><span style=\"font-weight: 400;\">The manuscript, published in Alzheimer&rsquo;s Research and Therapy, concludes that the pre-specified analysis showed consistent reduction of clinical decline across several clinical and biomarker endpoints at the highest doses.</span></p>\n<p><span style=\"font-weight: 400;\">The firms are aiming to confirm the results in the Phase III Clarity AD study.</span></p>\n<p><span style=\"font-weight: 400;\">In addition, the Phase III AHEAD 3-45 clinical study is exploring lecanemab in individuals with pre-clinical AD, defined as patients that are clinically asymptomatic, but have intermediate or elevated brain A&beta; levels.</span></p>\n<p><span style=\"font-weight: 400;\">Neurology chief clinical officer Michael Irizarry said the findings were &ldquo;exciting for the field and provide the opportunity to further explore the key role of the amyloid beta pathway in the pathophysiology of Alzheimer's disease.&rdquo;</span></p>\n<p><span style=\"font-weight: 400;\">He added: &ldquo;Eisai&rsquo;s precision pipeline approach envisions an Alzheimer&rsquo;s disease treatment paradigm based on a person&rsquo;s pathophysiological biomarker profile along the disease continuum.&rdquo;</span></p>\n<p><span style=\"font-weight: 400;\">As well as lecanemab, Eisai is developing a number of other targeted investigational compounds with the goal of making a breakthrough in this treatment setting.</span></p>", "date": "2021-04-20 12:53:00", "meta_title": NaN, "meta_keywords": "lecanemab, Phase, clinical, results, Eisai, working, published, number, therapy, study, Alzheimers, treatment, small, increasingly, players, disease, major", "meta_description": "Japanese drugmaker Eisai, one of an increasingly small number of major players still working in the Alzheimer\u00e2\u0080\u0099s space, has published results from a Phase IIb tr", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-20 12:52:58", "updated": "2021-04-20 13:56:13", "access": NaN, "url": "https://www.thepharmaletter.com/article/encouraging-phase-ii-data-for-alzheimer-s-candidate-ban2401", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "japan_big.jpg", "image2id": "japan_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "CNS Diseases, Neurological", "topic_tag": "Drug Trial, Research", "geography_tag": "Japan, Sweden", "company_tag": "BioArctic, Eisai", "drug_tag": "BAN2401, lecanemab", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-20 12:53:00"}